Gelonghui, April 9, 丨 Li Sheng Pharmaceutical (002393.SZ) said on the investor interactive platform that our main products include Subisan indapamide tablets, Sanyu Jingxing tablets, Siffonil Cefdinil dispersible tablets, friendly hemp seed softgels, biochemical nadroparin calcium injections, biohydrogenated sodium trisphate lyophilized powder, sodium bicarbonate tablets, sodium bicarbonate tablets, and a series of vitamin tablets. Up to now, the indications of the company's current products and products under development have not covered the field of prevention and treatment of nuclear radiation.
力生制药(002393.SZ)：现有产品以及在研产品的适应症没有涉及预防和治疗核辐射领域
Lisheng Pharmaceuticals (002393.SZ): Existing products and product indications under development do not cover the field of prevention and treatment of nuclear radiation
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.